BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Athersys, Inc. Release: MultiStem® Cell Therapy May Overcome Major Challenges in Organ Transplantations


7/9/2013 9:32:03 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CLEVELAND, July 9, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that an international team of researchers has published study results in STEM CELLS Translational Medicine demonstrating that Multipotent Adult Progenitor Cells (MAPCTM) increase the long-term survival of organ transplants in instances when the cell donor is not related to the patient or the organ donor, and also appear to alleviate the need for long-term immune suppression. The preclinical research, conducted using a standard heart transplant model, also demonstrated that the transplanted organ retained its immunologically privileged state during a subsequent transplantation procedure into a naïve recipient, illustrating the durability of the effect. The risk of rejection and the requirement for long-term immunosuppression are key challenges in donor organ transplantations, which could be addressed by administering the clinical MAPC product, MultiStem®, to transplant patients.

Help employers find you! Check out all the jobs and post your resume.


Read at GlobeNewswire

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES